【摘要】 目的:阐明线粒体转录终止因子3(mitochondrial transcription termination factor 3,MTERF3)在乳腺癌中的表达及其与患者临床病理特征、预后的相关性。方法:使用免疫组化SP法对58例乳腺癌组织及配对癌旁组织中MTERF3蛋白的表达水平进行检测。通过R 4.2.0软件获取癌症基因组图谱(The Cancer Genome Atlas, TCGA)数据库中705例乳腺癌患者的MTERF3 mRNA表达数据集、临床病理信息及预后资料，差异分析MTERF3表达量与乳腺癌患者临床病理参数之间的相关性，并使用UALCAN数据库进行可视化分析。使用Kaplan-Meier法计算患者的总体生存率和无疾病进展生存率，Cox回归分析影响乳腺癌患者预后的临床病理因素。结果:MTERF3蛋白主要表达于细胞质，且乳腺癌组织阳性表达率(91.38%)明显高于乳腺癌癌旁组织(20.69%),两组间阳性率具有显著差异(P<0.01)。TCGA数据集研究表明，MTERF3与乳腺癌患者的ER状态、PR状态、乳腺癌分子分型、癌症类型、组织学诊断及原发部位存在显著相关性(均P<0.05),但与患者的年龄、性别、T分期、N分期、M分期、AJCC病理分期、HER2状态以及有无恶性肿瘤病史无关。MTERF3与乳腺癌患者的总体生存时间和无疾病进展生存时间无关(P> 0.05)。Cox多因素分析提示，年龄、M分期和病理类型可能是导致乳腺癌患者预后不良的独立危险因素(P <0.05)。结论:MTERF3蛋白在乳腺癌组织中的表达阳性率和表达量均显著增高，提示MTERF3可能与乳腺癌的发生过程密切相关，该基因有望成为乳腺癌患者临床诊断和治疗的潜在基因靶点。更多还原

【Abstract】 Objective:To elucidate the expression of mitochondrial transcription termination factor 3(MTERF3) in breast cancer and its correlation with the clinicopathological characteristics and prognosis of patients.Methods:The expression levels of MTERF3 protein in 58 breast cancer tissues and paired paracancerous tissues were examined using the immunohistochemical SP method.The MTERF3 mRNA expression dataset, clinicopathological information and prognostic information of 705 breast cancer patients in The Cancer Genome Atlas(TCGA) database were obtained by R 4.2.0 software, and the correlation between MTERF3 expression and clinicopathological parameters of breast cancer patients was differentially analysed and visualised using the UALCAN database for visual analysis.Overall survival of patients and disease-free progression survival were calculated using the Kaplan-Meier method and Cox regression analysised clinicopathological factors affecting the prognosis of breast cancer patients.Results:MTERF3 protein was mainly expressed in the cytoplasm, and the positive expression rate in breast cancer tissues(91.38%) was significantly higher than that in breast cancer paracancer tissues(20.69%),with a significant difference in the positive rate between the two groups(P<0.01).The TCGA dataset study showed that MTERF3 was significantly correlated with ER status, PR status, breast cancer molecular staging, cancer type, histological diagnosis, and primary site of breast cancer patients(P<0.05).But not with patients’ age, gender, T-stage, N-stage, M-stage, AJCC pathological stage, HER2 status and history of malignancy.MTERF3 was not associated with overall survival time and disease-free survival time in breast cancer patients(P>0.05).Cox multifactorial analysis suggested that age, M stage and type of pathology may be independent risk factors for poor prognosis in breast cancer patients(P<0.05).Conclusion:The positive rate and expression of MTERF3 protein were significantly increased in breast cancer tissues, suggesting that MTERF3 may be closely related to the process of breast cancer development, and this gene is expected to be a potential gene target for clinical diagnosis and treatment of breast cancer patients.更多还原